Tag Archives: GlaxoSmithKline

GlaxoSmithKline PLC (NYSE:GSK) Puts Forward Petition to Japanese MHLW, Power One Inc. (NASDAQ:PWER) Getting Purchased by ABB

Posted on April 22, 2013 by Thomas Vedder

GlaxoSmithKline PLC (NYSE:GSK) and Theravance, Inc. reported on Monday they have submitted a regulatory petition to the Japanese Ministry of Health, Labour and Welfare, or MHLW, for the investigational once-daily LAMA/LABA combination medicine, UMEC/VI–with the planned proprietary name ANORO, ELLIPTA, …

Posted in Latest Headlines | Tagged ABB, GlaxoSmithKline, GSK, NYSE:ABB, NYSE:GSK | Comments Off

Review of Health Care Stocks with Key Moves: Valeant Pharmaceuticals (NYSE:VRX), Obagi Medical Products (NASDAQ:OMPI) – VRX, OMPI, GSK, PGNX, THC, OMPI

Posted on April 4, 2013 by Thomas Vedder

Healthcare sector reacted negatively on Wednesday trading session and sector plunged -0.85%. If we consider key movers of the sector so Progenics Pharmaceuticals, Inc (NASDAQ:PGNX) and Tenet Healthcare Corp (NYSE:THC) were major percentage decliner while key percentage gainer was Obagi …

Posted in Healthcare, Latest Headlines | Tagged GlaxoSmithKline, GSK, NASDAQ:OMPI, NASDAQ:PGNX, NYSE:GSK, NYSE:THC, NYSE:VRX, Obagi Medical Products, OMPI, PGNX, Progenics Pharmaceuticals, Tenet Healthcare, THC, Valeant Pharmaceuticals, VRX | Comments Off

Sanofi (NYSE:SNY) to Build New Plant in Vietnam to Meet Higher Demand; $75 Million Plan – SNY, BMY, GSK, MRK

Posted on April 1, 2013 by Thomas Vedder

Sanofi SA (ADR) (NYSE:SNY) announced on Friday that it will invest $75 million in a new facility in Vietnam to meet higher demand in the country for pharmaceuticals and consumer healthcare products.

French pharmaceutical company announced on Friday that the …

Posted in Healthcare, Latest Headlines | Tagged BMY, Bristol-Myers Squibb, GlaxoSmithKline, GSK, Merck, MRK, NYSE:BMY, NYSE:GSK, NYSE:MRK, NYSE:SNY, Sanofi SA, SNY | Comments Off

Santarus (NASDAQ:SNTS) Stock Hikes as Profit Outshines Forecasts

Posted on March 5, 2013 by Thomas Vedder

Santarus, Inc (NASDAQ:SNTS) stock surged 11% in afterhours trading session on Monday after the San Diego, California based company announced better-than-forecasted results for the fiscal Q4 and also estimate earnings for fiscal 2013 more than analysts’ forecasts.

The company announced …

Posted in Healthcare, Main Post | Tagged GlaxoSmithKline, GSK, Merck, MRK, NASDAQ:SLXP, NASDAQ:SNTS, NYSE:GSK, NYSE:MRK, Salix Pharmaceuticals, Santarus, SLXP, SNTS | Comments Off

Warner Chilcott (NASDAQ:WCRX) Beats Fiscal Fourth Quarter Results – WCRX, ACT, NVS, GSK

Posted on February 25, 2013 by Thomas Vedder

The Dublin, Ireland-based Warner Chilcott Plc (NASDAQ:WCRX) announced fiscal Q4 profit hiked from previous year, showing lower costs and sales expenses in many key promoted products, mainly LO Loestrin FE and Asacol. Both adjusted cash EPS and quarterly revenues surpassed …

Posted in Healthcare, Latest Headlines | Tagged ACT, Actavis, GlaxoSmithKline, GSK, NASDAQ:WCRX, Novartis AG, NVS, NYSE:ACT, NYSE:GSK, NYSE:NVS, Warner Chilcott, WCRX | Comments Off

Amicus Therapeutics (NASDAQ:FOLD) Stock Tumbles after Negative Results from Fabry

Posted on February 16, 2013 by Thomas Vedder

Amicus Therapeutics, Inc’s (NASDAQ:FOLD) stock fell on Friday after the Cranbury, New Jersey based company booked new negative results from a clinical inquiry of an experimental treatment for Fabry disease, a rare genetic disorder.

Amicus Therapeutics reported the medicine, migalastat, …

Posted in Healthcare, Main Post | Tagged Amicus Therapeutics, BioMarin, BMRN, FOLD, GlaxoSmithKline, GSK, NASDAQ:BMRN, NASDAQ:FOLD, NYSE:GSK, NYSE:PLX, PLX, Protalix BioTherapeutics | Comments Off

Stock Market Quotes and Streaming Charts - QuoteDaddy.com Level 2 Stock Quotes from Quote Daddy on Vimeo.

blogs

Lorimer Wilson Analyst

Dian L. Chu "EconMatters"

Paul Ebeling Trading News

Warren Bevan Precious Metals

eStocksDaily.com ("ESD") is not an investment advisory service, nor a registered investment advisor or broker-dealer and does not purport to tell or suggest which securities customers should buy or sell for themselves. The employees or affiliates of ESD may hold positions in the stocks or industries discussed here. You understand and acknowledge that there is a very high degree of risk involved in trading securities. ESD, the authors, the publisher, and all affiliates of ESD assume no responsibility or liability for your trading and investment results. Factual statements on the ESD's website, or in its publications, are made as of the date stated and are subject to change without notice. For ESD full disclaimer and disclosure go to our disclaimer page.It should not be assumed that the methods, techniques, or indicators presented in these products will be profitable or that they will not result in losses. Past results of any individual trader or trading system published by ESD are not indicative of future returns by that trader or system, and are not indicative of future returns which be realized by you. In addition, the indicators, strategies, columns, articles and all other features of ESD's products (collectively, the "Information") are provided for informational and educational purposes only and should not be construed as investment advice. Examples presented on ESD's website are for educational purposes only. Such set-ups are not solicitations of any order to buy or sell. Accordingly, you should not rely solely on the Information in making any investment. Rather, you should use the Information only as a starting point for doing additional independent research in order to allow you to form your own opinion regarding investments. You should always check with your licensed financial advisor and tax advisor to determine the suitability of any investment.